Dogwood Therapeutics, Inc. Increase (Decrease) in Accrued Salaries
Dogwood Therapeutics, Inc. (DWTX) reported Increase (Decrease) in Accrued Salaries of -$378.83 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedSalaries · last filed 2023-03-14
- Dogwood Therapeutics, Inc. increase (decrease) in accrued salaries for the quarter ending 2021-12-31 was $0.00.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued salaries for the quarter ending 2021-09-30 was $0.00.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued salaries for the quarter ending 2021-06-30 was $0.00.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued salaries for the quarter ending 2021-03-31 was -$378.83K, a 1398.84% decline year-over-year.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued salaries for fiscal 2021 was -$378.83K.
- Dogwood Therapeutics, Inc. increase (decrease) in accrued salaries for fiscal 2020 was -$144.29K.
| Period end | Increase (Decrease) in Accrued Salaries 3 month | Increase (Decrease) in Accrued Salaries 6 month | Increase (Decrease) in Accrued Salaries 9 month | Increase (Decrease) in Accrued Salaries 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $0.00 derived: sum of 2 quarters · filed 2023-03-14 | $0.00 derived: sum of 3 quarters · filed 2023-03-14 | -$378.83K 10-K · filed 2023-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | -$378.83K 10-Q · filed 2022-11-14 | -$478.83K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$378.83K 10-Q · filed 2022-08-12 | -$478.83K derived: sum of 3 quarters · filed 2022-08-12 | -$478.83K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$378.83K 10-Q · filed 2022-05-13 | -$478.83K derived: sum of 2 quarters · filed 2022-05-13 | -$478.83K derived: sum of 3 quarters · filed 2022-05-13 | -$552.29K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$100.00K derived: sum of 2 quarters · filed 2022-03-18 | -$173.45K derived: sum of 3 quarters · filed 2022-03-18 | -$144.29K 10-K · filed 2022-03-18 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$73.45K derived: sum of 2 quarters · filed 2021-11-12 | -$44.29K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$73.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$44.29K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $29.17K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |